Imperial College London
Portrait Picture

Mr Prakash P Punjabi

Faculty of Medicine, National Heart & Lung Institute

Professor of Practice (Cardiothoracic Surgery)
 
 
 
//

Contact

 

+44 (0)20 3313 2026p.punjabi Website

 
 
//

Location

 

BN2/25 B BlockHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ben-Aicha:2022:10.1177/02676591211056559,
author = {Ben-Aicha, S and Buchanan, J and Punjabi, P and Emanueli, C and Moscarelli, M},
doi = {10.1177/02676591211056559},
journal = {Perfusion (United Kingdom)},
pages = {1--11},
title = {Efficacy of treatments tested in COVID-19 patients with cardiovascular disease. A meta-analysis},
url = {http://dx.doi.org/10.1177/02676591211056559},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundThe COVID-19 pandemic has spread globally infecting and killing millions. Those with cardiovascular disease (CVD) are at higher risk of increased disease severity and mortality. We performed a systematic review and meta-analysis to estimate the rate of in-hospital mortality following different treatments on COVID-19 in patients with CVD.MethodsPertinent articles were identified from the PubMed, Google Scholar, Ovid MEDLINE, and Ovid EMBASE databases. This study protocol was registered under PROSPERO with the identifier CRD42020183057.ResultsOf the 1673 papers scrutinized, 46 were included in the review. Of the 2553 patients (mean age 63.9 ± 2.7 years/o; 57.2% male), the most frequent CVDs were coronary artery disease (9.09%) and peripheral arterial disease (5.4%) and the most frequent cardiovascular risk factors were hypertension (86.7%) and diabetes (23.7%). Most patients were on multiple treatments. 14 COVID-19 treatments were compared with controls. The pooled event rate for in-hospital mortality was 20% (95% confidence interval (CI): 11–33%); certain heterogeneity was observed across studies.ConclusionsCOVID-19 is associated with a high in-hospital mortality rate in patients with CVD. This study shows that previous CVD determines mortality, regardless of the type of COVID-19 administered therapy. Treatments for at-risk patients should be administered carefully and monitored closely until further data are available.
AU  - Ben-Aicha,S
AU  - Buchanan,J
AU  - Punjabi,P
AU  - Emanueli,C
AU  - Moscarelli,M
DO  - 10.1177/02676591211056559
EP  - 11
PY  - 2022///
SN  - 1477-111X
SP  - 1
TI  - Efficacy of treatments tested in COVID-19 patients with cardiovascular disease. A meta-analysis
T2  - Perfusion (United Kingdom)
UR  - http://dx.doi.org/10.1177/02676591211056559
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000765106300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR  - https://journals.sagepub.com/doi/10.1177/02676591211056559
ER  -
Download